13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q2 2023 · Filed May 9, 2023 · Accession 0001910264-23-000002
Total Value
$240.4M
Positions
5
Other Managers
0
Confidential Omitted
No
Holdings (5)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ARCELLX INC. | ACLX | 5,500,007 | $169.5M | 70.50% |
| 2 | DESIGN THERAPEUTICS INC | DSGN | 6,526,476 | $37.7M | 15.67% |
| 3 | ARS PHARMACEUTICALS | SPRY | 4,012,903 | $26.1M | 10.87% |
| 4 | NKARTA INC. | NKTX | 1,333,333 | $4.7M | 1.97% |
| 5 | EFFECTOR THERAPEUTICS INC | 28202V108 | 6,822,114 | $2.4M | 0.99% |